Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

NCT03214250 is registered in ClinicalTrials.gov with Parker Institute for Cancer Immunotherapy as lead sponsor.

NCT NCT03214250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03214250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Parker Institute for Cancer Immunotherapy
Phase
Phase 1/2
Overall status
Completed
Start date
July 21, 2017
Completion date
February 25, 2022
Enrollment
129 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma